



SCS
Swiss Chemical
Society

Community News

www.scg.ch

www.chemanager-online.com

SWISS CHEMICAL SOCIETY NEWS

Dr. Shi-Xia Liu to head a newly opened research laboratory at the University of Bern




Thanks to the support of the Bernese entrepreneur and Honorary Senator of the University of Bern, Walter Inäbnit, the University of Bern has recently established the “W. Inäbnit Laboratory for Molecular Quantum Materials” at the Department of Chemistry, Biochemistry and Pharmaceutical Sciences.

The newly opened laboratory will be headed by PD **Dr. Shi-Xia Liu**. As a long-time member of the University of Bern, Dr. Liu has been pioneering interdisciplinary research at the interface between synthetic chemistry, ultrafast spectroscopy and surface physics. In collaboration with quantum physics groups at the University of Basel, she explores the use of aromatic molecules as topologically protected superconducting quantum bits (qubits). The establishment of this new laboratory will allow Dr. Liu to push the boundaries of her innovative research into novel dimensions of materials chemistry.

Source: <https://www.unibe.ch>

NCCR Catalysis Young Talents Fellowship 2025: Call for Applications



Chemistry and catalysis impact our daily lives, but not everyone has the same opportunities to get involved in the catalysis and sustainable chemistry research community.


With the Young Talents Fellowship, the NCCR Catalysis aims to identify and promote students with an exceptional academic record, especially those facing

barriers in the current structures. The fellowship provides successful applicants with the opportunity to conduct their master thesis project in one or several research groups associated with NCCR Catalysis, and to establish their connections and ideas in a multidisciplinary, cross-fertilizing environment of research excellence.

Deadline for application is April 30, 2025.

More information: <https://nccr-catalysis.ch>

CIAAW Student Observer Grant 2025: Call for Applications



The Commission on Isotopic Abundances and Atomic Weights (CIAAW) invites applications for the Student Observer Grant to attend its biannual meeting in Tokyo, Japan, September 1-5, 2025. This grant is intended to support undergraduate students, graduate students, or recent PhD graduates (maximum two years post-PhD completion, or a similar stage of academic development) who have


(hands-on) expertise in isotope ratio analysis and atomic weight determination or in data processing in this field. See full details including Eligibility criteria, Grant coverage, Application process @ciaaw.org/student-grant.htm

Deadline for application is April 15, 2025.

The selection will be based on academic merit, relevance of expertise, and especially motivation. Final decisions will be communicated after the interview stage.

Source: <https://ciaaw.org/student-grant.htm>

The Top Ten Emerging Technologies in Chemistry: Call for Proposals for 2025




The International Union of Pure and Applied Chemistry IUPAC has released its call for proposals to identify the top ten emerging technologies in chemistry with the results to be announced in 2025. The Editorial Board of Chemistry International (CI) initiated a search for the Top Ten Emerging Technologies in Chemistry to kick-off IUPAC's

centenary year in 2019. The results were published in the 2019 April issue of CI and one of those technologies actually won the Nobel Prize in chemistry in 2021. The project was so successful that it has been repeated every year since and has met its objective of giving visibility and recognition to the role of chemists and chemistry in solving Society's greatest challenges as well as increasing IUPAC's visibility around the globe. The call for 2025 nominations is now open. Proposals are due by midnight on April 30, 2025.

Source: <https://iupac.org>

HONORS, AWARDS, APPOINTMENTS

Honorary Doctorate from Charles University Prague to Prof. Michael Grätzel, EPFL Lausanne



Prof. Michael Grätzel, EPFL Lausanne receives a Doctor Honoris Causa degree from Charles University in Prague as one of the most important researchers in chemistry of our time. The degree was conferred to him at a ceremony on 4 March 2025 at the Great Hall of the Karolinum, the historical seat of Charles University. Professor

Grätzel is world-renowned for inventing the first dye-sensitive solar cell in 1991 with chemist Brian O'Reagan. Just as plants use chlorophyll to turn sunlight into energy, the "Grätzel cells" use industrial dyes, pigments or quantum dots stimulated by sunlight to transmit an electrical charge. Within fifteen years of the original invention, Grätzel evolved the cells into an applied technology that is now being developed in universities and companies worldwide.

Source: <https://actu.epfl.ch>

JOURNAL NEWS

Helvetica, Volume 108, Issue 2, February 2025



Synthetic Procedure

Development of a Safe and Efficient Continuous Flow Method for the Synthesis of 3-Difluoromethoxy-pyridine Derivatives

Hansjoerg Lehmann, Thomas Ruppen, Susanne Oswald, Ning Ye, Xiangguang Tian, Xingxian Gu, Chunhui Dai, Robin A. Fairhurst

Research Article

Interactions and Click Functionalization of a Poly(Thiophenyl-Tetrazine-Co-Fluorene) Conjugated Polymer with Single-Walled Carbon Nanotubes

Shagana Kukendran, Sara Salimi, Alex Adronov

A Crystal Structure of an Oligoproline Hexamer with a Zig-zag Arrangement

Tobias Schnitzer, Joseph F. Woods, Nils Trapp, Helma Wennemers

Single Molecule Conductance of Anthraquinone-Based Molecular Wire: Effect of the Anchoring Group

František Vavrek, Jindřich Gasior, Jakub Šebera, Michal Valášek, Gábor Mészáros, Magdaléna Hromadová

Neutralization of an Oxytocin Derivative by 355 nm Photocleavage in High Vacuum

Yong Hua, Daniel Häussinger, Marcel Mayor, Valentin Köhler, Marcel Strauss, Martin F. X. Mauser, Tim Kistersitz, Philipp Geyer, Markus Arndt

Amoxicillin Concentrations in Samples of Musculoskeletal Infections

Joana Erdmann, Richard Kuehl, Mario Morgenstern, Dirk Bumann, Martin Clauss, Nina Khanna, Katharina M. Rentsch

INDUSTRIAL NEWS

Source: www.chemanager-online.com

Novartis to Acquire Anthos Therapeutics

Addition to Late-Stage Cardiovascular Pipeline February 11, 2025: Swiss drugmaker Novartis has agreed to acquire Anthos Therapeutics, a Boston, US-based biopharmaceutical company with its lead compound abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Under the terms of the agreement, Novartis will make an upfront payment of \$925 million upon closing of the transaction and potential additional payments of up to \$2.15 billion upon achievement of certain regulatory and sales milestones. The transaction is expected to close in the first half of 2025, subject to customary closing conditions. Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis. Abelacimab is a novel, highly selective, fully human monoclonal antibody that provides effective anticoagulation by inhibiting Factor XI, thereby minimizing blood clotting. Abelacimab is currently in Phase 3 development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation. "We are excited to join forces to advance the development of abelacimab, a potential first-in-class treatment and safer approach for stroke prevention in atrial fibrillation as well as cancer-associated thrombosis," said Shreeram Aradhya, president, Development and chief medical officer at Novartis. In July 2022 abelacimab received a Fast Track Designation from the FDA for the treatment of thrombosis associated with cancer. In September 2022, the compound was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation. "Abelacimab is a potential first-in-class medicine, which promises to be an effective and safer approach to preventing thrombosis and stroke than the current standards of care," said David Soergel, global head, Cardiovascular, Renal and Metabolism Development Unit at Novartis.